Skip to main content

Table 2 Frequentist analysis of the diabetes data [21]. The entry in row i and column j gives one minus the one-sided p-value of rejecting the null hypothesis that the treatment in the row (i) is worse than the treatment in the column (j) in favor of superiority of i compared to j

From: Ranking treatments in frequentist network meta-analysis works without resampling methods

  acar benf metf migl piog plac rosi sita sulf vild
acar 0.62 0.13 0.37 0.18 1.00 0.07 0.74 0.95 0.63
benf 0.38 0.11 0.28 0.13 0.99 0.05 0.64 0.80 0.53
metf 0.87 0.89 0.74 0.50 1.00 0.26 0.93 1.00 0.87
migl 0.63 0.72 0.26 0.29 1.00 0.14 0.82 0.94 0.72
piog 0.82 0.87 0.50 0.71 1.00 0.32 0.91 0.99 0.85
plac 0.00 0.01 0.00 0.00 0.00 0.00 0.05 0.04 0.02
rosi 0.93 0.95 0.74 0.86 0.68 1.00 0.96 1.00 0.92
sita 0.26 0.36 0.07 0.18 0.09 0.95 0.04 0.64 0.40
sulf 0.05 0.20 0.00 0.06 0.01 0.96 0.00 0.36 0.25
vild 0.37 0.47 0.13 0.28 0.15 0.98 0.08 0.60 0.75
  1. Abbreviations: acar acarbose, benf benfluorex, metf metformin, migl miglitol, piog pioglitazone, plac placebo, rosi rosiglitazone, sita sitagliptin, sulf sulfonylurea alone, vild vildagliptin
\